DIP
VRTX icon

DT Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

DT Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9K Hold
44
– – ﹤0.01% 318
2026
Q1 		$19.6K Hold
44
– – ﹤0.01% 325
2025
Q4 		$19.9K Hold
44
– – ﹤0.01% 335
2025
Q3 		$17.2K Hold
44
– – ﹤0.01% 350
2025
Q2 		$19.6K Hold
44
– – ﹤0.01% 330
2025
Q1 		$21.3K Hold
44
– – ﹤0.01% 313
2024
Q4 		$17.7K Hold
44
– – ﹤0.01% 339
2024
Q3 		$20.5K Buy
44
+29
+193% +$13.9K ﹤0.01% 351
2024
Q2 		$7.03K Hold
15
– – ﹤0.01% 405
2024
Q1 		$6.27K Hold
15
– – ﹤0.01% 369
2023
Q4 		$6.69K Hold
15
– – ﹤0.01% 362
2023
Q3 		$5.22K Hold
15
– – ﹤0.01% 371
2023
Q2 		$5.22K Hold
15
– – ﹤0.01% 378
2023
Q1 		$5.17K Hold
15
– – ﹤0.01% 376
2022
Q4 		$4.33K Hold
15
– – ﹤0.01% 402
2022
Q3 		$4K Buy
+15
New +$4.32K ﹤0.01% 384

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DT Investment Partners's VRTX Position: Q2 2026 in Review

DT Investment Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 44 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #318.

DT Investment Partners first reported a position in VRTX in Q3 2022 and has held it in 16 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • DT Investment Partners held 44 shares of Vertex Pharmaceuticals worth $21.9K as of Q2 2026.
  • DT Investment Partners left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of DT Investment Partners's portfolio in Q2 2026, its #318 holding.
  • DT Investment Partners first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on DT Investment Partners's 13F filing for Q2 2026, filed 27 Jul 2026.